• SENSEX
    NIFTY 50
Healthcare

Gilead plans to produce 2 million courses of potential COVID-19 drug remdesivir by 2020 end

Updated : June 22, 2020 08:33 PM IST

Remdesivir, which is currently administered intravenously, is the first drug to show effectiveness against COVID-19 in human trials.
Its emergency use has been permitted by several countries including the United States.
Gilead plans to produce 2 million courses of potential COVID-19 drug remdesivir by 2020 end

You May Also Like

Live TV

recommended for you

Advertisement